Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Patterns of recurrence after perioperative FLOT for resectable gastric cancer: A systematic review and meta-analysis.

Nancy Nguyen, Farris Al-Manaseer, Derek Tai et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16094

e16094 Background: Despite curative-intent resection and perioperative chemotherapy, gastric and gastroesophageal cancer (...

Spatial transcriptomics–guided computational pathology model to stratify docetaxel benefit in metastatic hormone-sensitive prostate cancer: CHAARTED trial (ECOG-ACRIN E3805).

Md Mamunur Rahaman, Sebastian R. Medina, Amritpal Singh et al. Jun 01, 2026 pp. 5002-5002 10.1200/jco.2026.44.16_suppl.5002

5002 Background: The CHAARTED trial demonstrated improved overall survival (OS) with the addition of docetaxel (DTX) to an...

Rural-urban disparities in chemotherapy administration and quality certifications in Minnesota.

Abigail Swenson, Collin Kray, Aidan Mayer Swenson et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13563

e13563 Background: Rural cancer patients experience disparities in access and outcomes compared to their urban counterpart...

Restoring form, rethinking function: The dual-edged impact of maxillofacial prostheses on survival and complication outcomes in head and neck cancer—A propensity matched analysis.

Minu Mohan, Joel Brian Epstein, Roberto Pili et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18125

e18125 Background: Maxillofacial prosthetic rehabilitation restores form and function in patients with head and neck cance...

OncoSphere AI: An agentic AI multidisciplinary clinical workflow support tool.

Aakash Desai, Ellen McNeeley, Sanad Alhushki et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13656

e13656 Background: Effective multidisciplinary cancer care is bottlenecked by the cognitive burden of synthesizing fragmen...

The characterization and management of immune checkpoint inhibitor–induced pruritus: A retrospective review.

Gabrielle Arkema, Allison Dobry, Busola Banjoh Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24167

e24167 Background: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies widely used in cancer treatment to block...

Surgical outcomes of sleeve versus standard lobectomy in patients with non–small cell lung cancer: A systematic review and meta-analysis.

Marcílio De Oliveira Filho, Jean Henri Maselli-Schoueri, Mariana Macambira Noronha et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20084

e20084 Background: Sleeve lobectomy is a parenchyma-preserving alternative to standard lobectomy for centrally located non...

Defining when and how to support palliative care communication: International consensus on timing and clinician training priorities for adolescents and young adults with cancer.

Ursula Sansom-Daly, Holly Evans, Madeleine Juhrmann et al. Jun 01, 2026 pp. 12103-12103 10.1200/jco.2026.44.16_suppl.12103

12103 Background: Early, developmentally appropriate palliative care communication is an international standard for adoles...

Molecular circulating tumor DNA (ctDNA) profiling from patients (pts) treated with zanidatamab + chemotherapy (CT) in first-line (1L) HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA).

Elena Elimova, Geoffrey Yuyat Ku, Keun-Wook Lee et al. Jun 01, 2026 pp. 4050-4050 10.1200/jco.2026.44.16_suppl.4050

4050 Background: Zanidatamab is a dual HER2-targeted bispecific antibody that binds to HER2 extracellular domains 2 and 4....

From awareness to action: A mixed-method community study on uptake of population-based breast cancer screening in an urban slum of Delhi.

Srishty Rajaura, Nidhi Bhatnagar, Tanya Singh Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13574

e13574 Background: Delayed diagnosis contributes to poor breast cancer outcomes in low-resource settings. We evaluated the...

Early burden reduction after two doses of cemiplimab in advanced non-melanoma skin cancer.

Lucrezia Raimondi, Francesca De Luca, Emmanuele De Luca et al. Jun 01, 2026 pp. 9583-9583 10.1200/jco.2026.44.16_suppl.9583

9583 Background: Advanced non-melanoma skin cancers (NMSC) frequently impose a high disease-related burden—severe pain, ul...

A phase I, open-label, dose-escalation study of CAR001 (mRNA-engineered Nb-CAR.BiTE-γδ T cells) in patients with relapsed or refractory solid tumors.

Der-Yang Cho, Tao-Wei Ke, Wen-Liang Huang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps2674

TPS2674 Background: Solid tumors are characterized by a highly immunosuppressive tumor microenvironment (TME). Key immune...

Determinants of cervical cancer awareness, procedural knowledge, and information sources among Nepali women undergoing HPV screening.

Jin Mou, Suchit Shashikumar, Gamala Luitel et al. Jun 01, 2026 pp. 11110-11110 10.1200/jco.2026.44.16_suppl.11110

11110 Background: Successful implementation of cervical cancer screening in low- and middle-income countries (LMICs) depen...

Phase II randomised controlled trial on postoperative radiotherapy, in high-risk, resected, non-medullary, non-anaplastic thyroid cancers (THYRO-RT).

Gouri Pantvaidya, Sarbani Ghosh-Laskar, Sandip Basu et al. Jun 01, 2026 pp. 6082-6082 10.1200/jco.2026.44.16_suppl.6082

6082 Background: Locally advanced thyroid cancers have high rates of locoregional recurrence after standard treatment with...

Biomarker study of BND-22 in combination with cemiplimab in solid tumors.

Mohamed H. Derbala, Cara L. Haymaker, Van K. Morris et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps2676

TPS2676 Background: Immune checkpoint inhibitors benefit only a subset of patients, indicating a need to identify other th...

Immune checkpoint inhibitor–induced autoimmune type 1 diabetes: Clinical characteristics and management outcomes from a multicenter retrospective study.

Prishita Banerji, Yajjat Garg Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23330

e23330 Background: Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 pathways have significantly impro...

Adebrelimab in combination with anlotinib and chemotherapy as neoadjuvant therapy for resectable stage II-III non–small cell lung cancer (NSCLC): A prospective, single-arm, phase II trial.

Meng Wang, Yu Zhang, Bin Jia et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20073

e20073 Background: Immunotherapy combined with chemotherapy as neoadjuvant treatment for NSCLC has demonstrated significan...

Longitudinal analysis of PD-1 receptor occupancy in spleen and tumor-infiltrating lymphocytes in a murine model.

Toshiaki Tsurui, Masahiro Hosonuma, Eiji Funayama et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14580

e14580 Background: Anti-PD-1 antibodies restore T-cell-mediated anti-tumor immune responses by blocking the interaction be...

Comparative real-world survival outcomes of ribociclib and abemaciclib in breast cancer.

Chinenye M. Okafor, Chinedum Enete, Mohammad Hatamleh et al. Jun 01, 2026 pp. 11167-11167 10.1200/jco.2026.44.16_suppl.11167

11167 Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), including ribociclib and abemaciclib, are widely used...

Tumor recurrence or treatment effect? Large multi-institutional evaluation of an AI risk assessment model in glioma and brain metastases.

Dheerendranath Battalapalli, Hyemin Um, Sunil Manjila et al. Jun 01, 2026 pp. 2080-2080 10.1200/jco.2026.44.16_suppl.2080

2080 Background: Distinguishing true tumor recurrence (TuR) from radiation necrosis (RN) on post-treatment MRI scans remai...

First-line GemCis ± immunotherapy vs FGFR inhibition in ctDNA-detected <i>FGFR2</i> fusion–positive advanced cholangiocarcinoma: A real-world analysis.

Richard D. Kim, Aidan Manning, Nicole Zhang et al. Jun 01, 2026 pp. 4159-4159 10.1200/jco.2026.44.16_suppl.4159

4159 Background: Advanced cholangiocarcinoma (aCCA) carries a poor prognosis. Approximately 40% of aCCA harbor targetable...

AI-driven TILs spatial analysis to identify high-density hot spots as a superior prognostic marker in triple-negative breast cancer.

Takuma Kobayashi, Kanako C. Hatanaka, Nobumoto Tomioka et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12562

e12562 Background: Tumor-infiltrating lymphocytes (TILs) are a robust prognostic biomarker in triple-negative breast cance...

Phase 1/2 study of CLIO-8221, a HER2-targeted, dual-payload exatecan and ATR inhibitor antibody-drug conjugate (ADC) in patients with advanced HER2-expressing solid tumors.

Timothy A. Yap, Charlotte Rose Lemech, Peter Kar Han Lau et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps3162

TPS3162 Background: CLIO-8221 is a novel anti-HER2 ADC designed to overcome topoisomerase 1 inhibitor (Topo1i) resistance...

Clinical significance of the preoperative cachexia index as a prognostic predictor in patients with extrahepatic cholangiocarcinoma undergoing radical surgery.

Qingyang Meng, Chunyan Wang, Wentao Sun et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16336

e16336 Background: The cachexia index (CXI) has been proven to have prognostic value in various tumors. Extrahepatic chola...

Oral mucin expression in the early diagnosis of esophagogastric cancer.

Nikhil Manish Patel, Pranav Patel, Ricky Harminder Bhogal et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16099

e16099 Background: Challenges in early diagnosis of esophagogastric carcinoma (EGC) may partly explain its poor long-term...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page